News Preview

Moderna, Merck’s experimental cancer vaccine cuts melanoma recurrence risk by 42%: Report

Moderna, Merck’s experimental cancer vaccine cuts melanoma recurrence risk by 42%: Report

An experimental cancer vaccine developed by Moderna and Merck has shown promising results in reducing the risk of melanoma recurrence. According to a report, the vaccine cut the risk by 42% in a phase 3 clinical trial. The vaccine, known as M7824, targets two proteins found in melanoma tumors.

Want to stay up to date with the world events at sea or at home?

Explore Navvyx News - the best News app for seafarers.